Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sevelamer carbonate is a non-absorbed phosphate binding polymer used to control serum phosphorus levels in adults and children (6 years and older) with chronic kidney disease (CKD) on dialysis. It works by binding dietary phosphate in the gastrointestinal tract, thereby reducing its absorption and lowering serum phosphorus concentrations. This helps prevent complications such as hypocalcemia and bone disorders associated with hyperphosphatemia in CKD patients. Sevelamer also binds bile acids, which can lead to reductions in total and LDL cholesterol. The drug is free of metal and calcium ions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sevelamer carbonate.